Howe & Rusling’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$61.1K Hold
386
﹤0.01% 368
2026
Q1
$49.3K Sell
386
-50
-11% -$6.24K ﹤0.01% 364
2025
Q4
$53.2K Buy
436
+50
+13% +$5.73K ﹤0.01% 366
2025
Q3
$38.7K Hold
386
﹤0.01% 358
2025
Q2
$32K Hold
386
﹤0.01% 369
2025
Q1
$31.3K Sell
386
-133
-26% -$11.9K ﹤0.01% 340
2024
Q4
$46.7K Buy
519
+19
+4% +$1.84K ﹤0.01% 318
2024
Q3
$49.4K Buy
+500
New +$49.1K ﹤0.01% 301
2022
Q2
Sell
-18
Closed -$2K 1170
2022
Q1
$2K Buy
+18
New +$1.66K ﹤0.01% 898
2020
Q3
Sell
-65
Closed -$7K 880
2020
Q2
$7K Buy
65
+27
+71% +$2.66K ﹤0.01% 495
2020
Q1
$3K Buy
+38
New +$3.37K ﹤0.01% 598
2019
Q1
Sell
-400
Closed -$29K 896
2018
Q4
$29K Buy
400
+100
+33% +$8.06K 0.01% 305
2018
Q3
$29K Buy
+300
New +$29.1K ﹤0.01% 341

Other funds holding XBI

Howe & Rusling's XBI Position: Q2 2026 in Review

Howe & Rusling held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 386 shares worth $61.1K. The position accounts for ﹤0.01% of the portfolio, ranked #368.

Howe & Rusling first reported a position in XBI in Q3 2018 and has held it in 13 quarters since. 934 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Howe & Rusling held 386 shares of State Street SPDR S&P Biotech ETF worth $61.1K as of Q2 2026.
  • Howe & Rusling left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Howe & Rusling's portfolio in Q2 2026, its #368 holding.
  • Howe & Rusling first reported a position in State Street SPDR S&P Biotech ETF in Q3 2018 and has held it in 13 quarters since.
  • 934 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Howe & Rusling's 13F filing for Q2 2026, filed 10 Aug 2026.